Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00095186
Recruitment Status : Completed
First Posted : November 2, 2004
Last Update Posted : April 10, 2008
Information provided by:

Brief Summary:
The purpose of this study is to determine if orally-administered recombinant human lactoferrin is effective in the treatment of advanced renal cell carcinoma (RCC) in patients who have failed at least one prior systemic therapy for RCC.

Condition or disease Intervention/treatment Phase
Carcinoma, Renal Cell Drug: Recombinant Human Lactoferrin Phase 2

Detailed Description:
This is an open label, multi-center Phase 2 study. Approximately 40 patients will be enrolled in a single study arm. RhLF, at a dose of 1.5 g [1 vial], twice a day (b.i.d.), will be administered orally for two cycles each of 12 consecutive weeks followed by 2 weeks off. A maximum of two additional cycles may be given if an objective response is obtained or if the patient has stable disease and no increase in the size of the target tumor(s) relative to either the Screening CT or the most recent CT measurement, measured according to RECIST prior to the additional cycle(s). Response and progression-free survival will be evaluated for the first 20 patients enrolled. If no patient has an objective response and less than 10% of the patients are alive and progression-free at 14 weeks from the start of Study Drug, then the study will be terminated. If in either Cycle 3 or Cycle 4, more than three out of the first ten patients or more than six out of the first twenty patients entering the cycle experience a Grade 3 or 4 Study-Drug-related adverse event, no further patients will advance into Cycle 3 or Cycle 4.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Phase 2, Open Label Study of Safety and Efficacy of Oral Recombinant Human Lactoferrin (rhLF) Monotherapy in Patients With Advanced Renal Cell Carcinoma (RCC), Who Have Failed at Least One Regimen of Systemic Therapy for RCC
Study Start Date : September 2004
Study Completion Date : March 2007

Primary Outcome Measures :
  1. Best Overall Response rate using RECIST criteria
  2. 14-WeekProgression-Free Survival (PFS) rate

Secondary Outcome Measures :
  1. 4 month and 8 month Progression-Free Survival (PFS) rates
  2. Median progression-free survival
  3. Median Overall Survival (OS) and 1-year OS rate
  4. Toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥18 years
  • Histologically confirmed, advanced or metastatic RCC with predominantly clear cell histology that is unresectable or medically inoperable.
  • Experienced and failed at least one regimen of systemic therapy for RCC with CT documentation of disease progression.
  • A previous CT (4 weeks or more prior to the Screening CT) showing progression of the target tumor(s) compared to a prior CT no more than 9 months previously
  • At least one target tumor lesion is measurable at Screening with CT scan, according to RECIST, and not previously irradiated
  • Karnofsky performance status of ≥70 (ECOG <2)
  • Able to understand and sign an informed consent

Exclusion Criteria:

  • Significant sarcomatoid, spindle cell, or nuclear grade 4 histology
  • Significant non-clear cell RCC (for example, papillary, chromophobe, collecting duct, granular, or unclassified RCC)
  • Total bilirubin >1.5 mg/dL
  • Serum creatinine >2.0 mg/dL
  • Hemoglobin <10.0 g/dL
  • Absolute neutrophil count <2000/mm3
  • Lymphocytes <800/mm3
  • Platelet count <100,000/mm3
  • AST (SGOT) or ALT (SGPT) ≥2.5 x institutional upper limit of normal
  • Serum calcium >11.5 mg/dl
  • International Normalized Ratio of Prothrombin Time (INR) >1.2
  • FEV1 <60% predicted or FVC <60% predicted by spirometry (both are to be measured)
  • Existing or history of brain metastases
  • History of allergic reactions to compounds of similar chemical or biologic composition to the Study Agent rhLF
  • Active ischemic heart disease, symptomatic congestive heart failure
  • Serious active infection
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Autoimmune diseases (e.g., systemic lupus erythematosus, multiple sclerosis or ankylosing spondylitis)
  • Other malignancies, except non-melanoma skin cancer, within 5 years of study entry
  • Radiotherapy within 4 weeks prior to study treatment start
  • Corticosteroid therapy within 4 weeks prior to treatment start, with the exception of inhaled or topical steroids
  • Chemotherapy/Immunotherapy (e.g., IL-2, INFα, tumor vaccine) within 4 weeks prior to study treatment start
  • Known HIV positive
  • Receipt of any investigational medication within 30 days prior to participation in the study
  • Pregnant or lactating patients, or fertile female patients with a positive pregnancy test (serum β-human chorionic gonadotropin [β-HCG] at Screening and on Day 1 prior to the first dose), or fertile female patients unwilling to use adequate contraception prior to study entry, during treatment and 30 days after completion of treatment
  • Sexually active male patients unwilling to practice contraception while participating on this study and up to 30 days after completion of treatment
  • Unable to take liquid medication by mouth or feeding tube

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00095186

Layout table for location information
United States, California
University of California
Los Angeles, California, United States, 90095
Stanford University School of Medicine
Stanford, California, United States, 94305
United States, Illinois
The University of Chicago Medical Center
Chicago, Illinois, United States, 66037
United States, Ohio
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States, 44195
United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
VA Medical Center/Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Ernest W. Yankee, Ph.D. Agennix, Inc.
Additional Information:
Layout table for additonal information Identifier: NCT00095186    
Obsolete Identifiers: NCT00099034
Other Study ID Numbers: LF-0209
First Posted: November 2, 2004    Key Record Dates
Last Update Posted: April 10, 2008
Last Verified: April 2008
Keywords provided by Agennix:
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Anti-Infective Agents